2^nd Asia Pacific Oncology and Cancer Conference December 07-08, 2020 Tokyo, Japan

The Conference Cancer Summit 2020

We are happy to welcome you to the official website webinar of 2^nd Asia Pacific Oncology and Cancer Conference (Cancer Summit 2020) during December 07-08, 2020 with the theme of "Explore the Latest Innovative Treatment and Prevention of Oncology and Cancer" which covers wide range of critically important sessions. It’s a platform to bring all the oncologists and Cancer specialists together to share their experiences it’s the amalgam of scientific research as well as innovative ideas. This includes prompt Keynote Presentations, Oral Talks, Poster Presentations, Video Presentations and Exhibitions.

Overview of Oncology and Cancer:

The Innovative idea of Cancer has started a great many research to be embraced by the labs around the world. With such an extraordinary number of researchers and scientists taking a shot at Caner research, till date, no significant solution for this is recorded. Global Cancer at Tokyo will manage Cancer Prevention, Diagnosis, and Treatment of illnesses of the Organ-related Cancers and its inventive strategies. Global Cancer  will also provide the two days of discussions on techniques and systems identified with administration and quality change of Cancer and in addition to investigate the new thoughts and ideas on worldwide scale and the themes incorporate lung malignancy, bosom disease, bone tumor, leukemia, blood cancer, cervical tumor, colon-rectum disease, pediatric malignancy, surgical tumor, Prostate growth, thyroid malignancy.

Global market is segmented into Europe, North America, Latin America, Asia pacific, and Middle East and Africa. According to market study, Market Value for  Oncology (i.e. on Organ defined Cancer and Tumors) will be more than double to $ 623 Million by 2020. A major part of research is going on the top Universities on across the globe. Many companies are associated with various Cancer Screening and Diagnostics instruments and other therapeutics. Besides this various societies, associations and research center are also associated in this research field.

This year around 764,800 Americans are expected to die of cancer more than 1,900 individuals a day Disease is the second driving reason for death in the US. One of each four passing’s in the US is from growth. Since 1990, there have been around 5 million malignancy deaths. Lung Cancer, Blood Cancer, Breast Cancer are most common Cancers in Japan.

As per 2012 insights around 14.1 million cases are passed on and 8.2 million deaths are accounted for. Lung, Brain, Stomach and bowel malignancies cause the most widely recognized deaths among the worldwide that records almost 60% of all the cancer deaths. Around 70% increments in the cases are not out of the ordinary throughout the following 2 decades. In males 5 most regular sites of malignancy are recognized in 2014 were lung, prostate, colorectal and liver diseases. In females 5 most shared locales analyzed were bosom, Ovary and stomach tumor.

Target Audience:

• Cancer Institutes (Professors, Associate Professors, Professionals, Lecturers, Scientists and students, Postdoctoral fellows, and Trainees)
• Cancer Pharmaceutical Companies
• Research scholars
• Pathologist
• Diagnostics companies
• Medical Practitioners
• Industrial Researchers
• Academicians
• Directors, Head of Department
• Chemotherapists
• Research and Development Department.
• Business Delegates
• Medical Colleges
• Rehabilitation Specialists
• Genetic scientists
• Cancer Associations
• Diagnostic Laboratory Professionals
• Hospital presidents/CEOs/COOs/VPs/trustees
• Hospital c-suite executives (operations, development, finance)
• Oncology specialists (medical, radiation, and surgical)
• Oncology program and practice administrators, managers, and service line executives
• Healthcare consultants, vendors, and suppliers
• Cancer program marketing and public relations professionals
• Exhibitors and people with keen interest in the research areas of Cancer Research.

Who should sponsor/exhibit:

• Basic and Translational Laboratory Researchers       
• Hospitals
• Educational Institutes
• Research Centres
• Charitable Foundations focused on funding research, advocating for and supporting the needs

Why to attend?

Oncology and Cancer will enlighten the audience with the most recent advancements in Cancer diagnosis, Cancer Science,Cancer therapy, Cancer treatment etc., around the world and to glow the related research ideas regarding Cancer Research & Oncology. Geographically people from around the world focused on getting some answers concerning Oncology and Cancer; this is your most obvious opportunity to accomplish the greatest cluster of individuals from the Cancer people group, Oncology Societies, Associations, European Oncology Conferences. Coordinate presentations, disperse information, meet with present and potential specialists, make a sprinkle with new pharmaceutical progressions, and get name affirmation at this two days event.

The aim of the Conference is to provide a platform to academicians and practitioners from multiple disciplines to debate and deliberate on social change that is encompassed by innovation and technology.

For more details please visit: https://cancer.cancersummit.org/

 Benefits of Attending the Conference:

• Networking Opportunities, Grow Your Professional Network
• Build Your Knowledge Base
• Expand Your Resources
• Meet Experts & Influencers Face to Face
• Learning in a New Space
• Break Out of Your Comfort Zone
• New Tips & Tactics
• Top Industries Representation
• Abstracts will be published in the conference souvenir and respective International journals
• Each Abstract will receive unique (DOI) Number provided by Cross Ref
• Website visibility to more than 35K visitors in less than 6 months
• Laudable talks by the top-notch of the Global Scientific Community
• The Serendipity of the Random Workshop
• Will be felicitated with International Organizing Committee Member (IOCM)
• Remarkable Awards and Global Recognition to meritorious Researchers

It is our pleasure to invite you for the conference “2^nd Asia Pacific Oncology and Cancer Conference” webinar going to be held during December 07-08, 2020 with the main theme of our conference is “ the Latest Innovative Treatment and Prevention of Oncology and Cancer chalenges with COVID-19 pandemic” which covers wide range of critically important sessions.

Cancer Summit 2020 is a stage to find out the Cause of the tumor, its Prevention, Diagnosis, and Treatment of the Organ-related Cancers and its inventive strategies. This Cancer Summit 2020 will have two days of dialogs on techniques and procedures which will be administered in Cancer and in addition to explore the frontiers and  ideas on worldwide scale and the points include lung cancer, breast cancer, bone cancer,  blood cancer, cervical cancer, colon-rectum cancer, prostate cancer, thyroid cancer.

Track 1: Fields of Oncology

Oncology and Cancer is the branch of medicine that researches, identifies and treats cancer. A physician who works in the field of oncology/Cancer is an oncologist.

Oncologists must first diagnose a cancer, which is usually carried out via biopsy, endoscopy, X-ray, CT scanning, MRI, PET scanning, ultrasound or other radio logical methods. Nuclear medicine technique can also be used to diagnose cancer, as can blood tests or tumor markers. Oncology is often linked with haematology oncology, which is the branch of medicine that deals with blood and blood-related disorders.

Track 2: Types of Oncology

Oncology is the study of tumor or cancer. Most of the tumors are not cancerous. The cancerous tumors are called malignant tumors. In general, oncology implies the study of malignant tumors or cancer. The doctor who practices oncology is an oncologist. There are different kinds of oncologists. Those who specialize in surgery are called surgical oncologists. Those who specialize in radiation therapy are called radiation oncologists. Those who specialize in the care of persons with cancer and administer chemotherapy are medical oncologists.

Track 3: Solid tumor

An abnormal mass of tissue and cells that usually does not contain cysts or liquid areas. Solid tumors may be benign Tumors (not cancer), or malignant (cancer). Different types of solid tumors are named for the type of cells. Examples of solid tumors are sarcomas, carcinomas, and lymphomas. Leukemias (cancers of the blood) generally do not form solid tumors.

There are two major types of solid tumors are sarcomas and carcinomas. Many types of solid tumors, whether a sarcoma or a carcinoma, are often treated with surgery.

1. Sarcomas are tumors in a blood vessel, bone, fat tissue, ligament, lymph vessel, muscle or tendon. There are many types of sarcomas. They include:

Ewing sarcoma and osteosarcoma, which are bone cancer sarcomas.

Rhabdomyosarcoma, which is a soft tissue sarcoma found in muscles.

2. Carcinomas are tumors that form in epithelial cells. Epithelial cells are found in the skin, glands and the linings of organs. Those organs includes the bladder, ureters and part of the kidneys.

One common carcinoma is adrenocortical carcinoma. This is when a tumor develops in one or both adrenal glands, located above each kidney.

Track 4: Neurosurgical Oncology

Neurosurgical Oncology is a complex surgical method that presupposes treatment, diagnosis, and rehabilitation of disorders affecting any region of the Nervous System. Some of the preponderance  are common Neuro surgeries are skull base surgery, Image Guided Surgery, Laser Surgery, Spinal Neurosurgery and Neuro surgical treatment.

Track 5: Nursing Oncology

A Nursing Oncology gives care to growth patients and those in danger for getting the sickness. They screen physical conditions, recommend solution, and oversee chemotherapy and different medications for cancer. Oncology and Cancer is a standout among the most difficult and remunerating fields in nursing. One of the essential parts of the cancer nurture is quiet appraisal. They are in charge of surveying patients who have introduced because of treatment reactions, and also evaluating patients, amid and post-chemotherapy. The oncology nurture must have the capacity to comprehend pathology comes about and their suggestions, and have an inside and out learning of the normal symptoms of growth medicines. The oncology nurture should likewise utilize her relational aptitudes to tune in to the patient, surveying their comprehension of the malady and its procedure and also the patient's passionate state.

Track 6: Medical & Radiation Oncology

Radiation Oncology encompasses all aspects of research that impacts on the treatment of oncology using radiation. Radotherapy can be given as a curative modality, either alone or in combination with surgery and/or chemotherapy. It may also be used palliative, to relieve symptoms in patients with incurable cancers. The Radiotherapy is broadly segmented into Radiotelegraphy, Brachy-radiotherapy and Metabolic Radiotherapy.

Track 7: Neuro Oncology

The Central Nervous System is denounced to various malevolent personality disorder. Central Nervous System covers its mechanism, Metastatic pestilence, Ramification, Cancers, Neurons and Sensory Receptors, Neurological Disorders, Multiple sclerosis and Imaging agents to CNS neurofibromatosis. Cancer spreads to the Nervous System by direct invasion or compression from continuous tissues relates to the proximity of the Nervous System to other structures. Central Nervous System Drugs market to grow at a CAGR of -3.2% over the period 2013-2018. The central nervous system (CNS) therapeutics peddle has been forecast to reach US$133 billion by the year 2018, which increases in disease ubiquity rates due to increase in population, introduction of new drugs, and increased outgo on healthcare

Track 8: Brain Tumor

Brain Tumor occurs when abnormal cells form inside the brain. The symptoms of Brain stem tumors vary greatly and can include Ataxia, Cranial Nerve Palsy, headaches, problems with speech and swallowing, hearing loss, weakness, Hemiparesis, vision abnormalities, ptosis, and behavioural changes. Another possible symptom is vomiting. Any brain tumor is inherently serious and life-threatening because of its infiltrative character in the limited space of the Intracranial Cavity.

Track 9: Cancer Cell Biology and genetics

Cancers are responsible for millions of death every year. The study of cancer biology is therefore one of the largest areas of scientific interest. Cancer cells develop specific hallmarks through a series of mutations in both oncogenes and tumour-suppressor genes. There is no definitive cure for cancer, the majority of cancer treatments serve to prolong the lives of cancer sufferers.

Track 10: Cancer Biomarkers

A cancer biomarker refers to a substance that is indicative of the presence of cancer in the body. A biomarker may be a molecule secreted a specific response of the body to the presence of cancer. Genetic, epigenetic, proteomic and imaging biomarkers can be used for cancer diagnosis, prognosis, and epidemiology. Ideally, such biomarkers can be assayed in non-invasively collected bio fluids like blood or serum.

While numerous challenges exist in translating biomarker research into the clinical space a number of gene and protein based biomarkers have already been used at some point for patient care; including, AFP (Liver Cancer), BCR-ABL (Chronic Myeloid Leukaemia), BRCA1 / BRCA2 (Breast/Ovarian Cancer), BRAF V600E (Melanoma/colorectal Cancer), CA-125 (Ovarian Cancer), CA19.9 (Pancreatic Cancer), CEA (Colorectal Cancer), EGFR (Non-small-cell lung carcinoma), HER-2 (Breast Cancer), KIT (Gastrointestinal stromal tumor), PSA (Prostate Specific Antigen) (Prostate Cancer), S100 (Melanoma), and many others. Mutant Proteins detected by Selected Reaction Monitoring (SRM) have been reported to be the most specific biomarkers for cancers because they can only come from an existing tumor.

Track 11: Cancer metabolomics

Cancer metabolomics research is being used to discover diagnostic cancer biomarkers in the clinic, to better understand its complex heterogeneous nature, to discover pathways involved in cancer that could be used for new targets and to monitor metabolic biomarkers during therapeutic intervention. Cancer metabolomics approaches may also provide clues to personalized cancer treatments by providing useful information to the clinician about the cancer patient’s response to medical interventions. The ultimate goal of most Cancer Metabolomics studies is to discover cancer-specific diagnostic, prognostic or predictive biomarkers for a patient.

Track 12: Organ-Defined Cancers

Cancer can occur anywhere in the body. The most common sites of cancer among men include lung, prostate, colon, rectum, stomach, Brain and liver. And those for among women are breast, colon, rectum, lung, cervix, ovarian and stomach. Cancers are often described by the body part that originated in. However, some body parts contain multiple types of tissue, so for greater precision, cancers can additionally be classified by the type of cell that the tumor cells originated from. The type of cancer a person has needed to be known properly as different types of cancer can behave very differently and respond to different treatments.

Track 13: Cancer: Psychological Aspects

If one is fighting cancer, it is not uncommon to experience psychological distress. Whether it is coping with the diagnosis, the challenges of treatment, or continued worry about a recurrence, emotions brought on by the cancer experience can be difficult to handle

Track 14: Lifestyle Changes to Improve Your Cancer Care

How we live can have pro­found effects on our health and wellness. This also applies for people who have cancer. A healthy lifestyle can support cancer treatments and help you feel better. It may also improve your long-term health.

Track 15: Cancer Epigenetics and Oncogenomics

Cancer is a genetic disease caused by accumulation of DNA mutations and epigenetic alterations leading to unrestrained cell proliferation and neoplasm formation. The ambition of oncogenomics is to identify new oncogenes or tumor suppressor genes that may provide new insights into cancer diagnosis, predicting clinical outcome of cancers and new targets for cancer therapies. The success of targeted cancer therapies such as Gleevec, Herceptin and a vastin raised the hope for oncogenomics to elucidate new targets for cancer treatment.

In cancers, loss of expression of genes occurs about more frequently by transcription silencing (caused by epigenetic promoter hypermethylation of CpG islands) than by mutations. Oncogenomics is a sub-field of genomics that characterizes tumor-associated genes.It concentrate on genomic, epigenomic and transcript alterations in cancer.

Track 16: Cancer Screening and Diagnostics

Cancer screening tests goal to find cancer early, before it causes symptoms and when it may be easier to treat successfully. Effective screening tests are those that:

• Reduce the chance that someone who screened regularly will die from the cancer.
• Have more potential benefits than harms. (Possible harms of screening tests include bleeding or other physical damage, inaccurate test results, and overdiagnosis—the diagnosis of cancers that would not have caused problems and did not need treatment.)
• Diagnosing of cancer at its earliest stages often provides the best chance for a cure.
• For few cancers, studies show screening tests can save lives by diagnosing cancer early. For other cancers, screening tests are recommended only for people with increased risk on their life.

Track 17: Cancer Vaccines

Cancer vaccines generally either treat existing cancer or prevent development of cancer. Cancer treatment vaccines are made up of cancer cells, parts of cells and pure antigens. Sometimes a patient’s own immune cells are removed and exposed to these substances in the lab to create the vaccines.

Tracks 18: Clinical Trials in Cancer Treatment

Phase l trials are the final step in a long process that begins with research in a lab. Before any advance treatment is used with people in clinical trials, researchers work for many years to understand its effects on cancer cells in the lab and in animals. They also try to figure out the side effects it may cause.

Track 19: INNOVATIONS IN CANCER RESEARCH AND ONCOLOGY

Continuous Anticancer drug discovery and development is critical to find a complete cure for cancer. Due to the drug resistance developed by tumour cells for existing treatments, this is becoming a mandatory approach to fight the disease.

• Scientific investigations on inhibitors of checkpoint CHK1 can be another milestone for anticancer drug discovery approach.
• Cancer cells are specifically dependent on molecular chaperones and related proteins that regulate homeostasis. These are promising targets for new anticancer therapies.
• Deregulated apoptosis is hallmark of cancer and Bcl-2 family of proteins are pivotal to mediating the pathway of this process. Inhibiting their process can be a significant way for developing new anticancer drugs. Many plant sources are known to be valuable sources of novel anti-cancer properties.

The term ‘cancer’ can be defined as the uncontrolled growth of cells in the body. It is an outcome of cascading events involving abnormal cell divisions. These cell divisions occur due to various biotic and abiotic factors. These factors may include physical exposure to certain substances or chemicals which are also termed as carcinogens; exposure to radiations that involve both ionizing and non-ionizing. Cancer is also known to be linked with some autoimmune diseases such as celiac disease, crohn’s disease. There are more than 200 types of cancer. Some diagnostic techniques are used to diagnose the cancer, cancer growth, affected area and severity of the disease such as MRI, CT Scan, PET scan, Ultrasound, some laboratory biochemical analysis tests, to detect the presence of excess levels of certain substances that may also be the cause of cancer.

Normally, human cells grow and divide to form new cells as the body needs them. When cells grow old or become damaged, they die, and new cells take their place. When cancer develops, however, this orderly process breaks down. As cells become more and more abnormal, old or damaged cells survive when they should die, and new cells form when they are not needed. These extra cells can divide without stopping and may form growths called tumors.

Importance and Scope

Cancer Summit 2020 will be the best platform for all the scientist, radiologists, oncologists, research scholars, students who are working in this field to exchange their knowledge related to Cancer and oncology. This international event is an effort to find an alternative for invasive imaging technique against cancer like Liver Cancer, Brain Cancer, Breast Cancer, Lung Cancer, Kidney Cancer, Cancer in adults & cancer in children.

North America is the leading regional marketplace for cancer diagnostics with a part of approximately 40.7% of the general cancer diagnostics market in terms of income in 2015, shadowed by Europe which accounted for around 29.1% share in the market.

Cancer Research Centres:

A. K. Khan Healthcare Trust
Aalborg Hospital - Department of Oncology
Aarhus University Hospital - Department of Oncology
Abbotsford Cancer Centre
bramson Cancer Center
ddenbrookes Oncology Centre
Aichi Cancer Center
Albert Einstein Cancer Center
Allan Blair Cancer Centre
Alvin J. Siteman Cancer Center
Arizona Cancer Center
Atlantic Cancer Research Institute
Azienda Ospedaliera Arcispedale S. Maria Nuova
Comprehensive Cancer Center Ulm
Comprehensive Cancer Center Vienna
Comprehensive Cancer Centre - Vratsa
Comprehensive Cancer Centre the Netherlands
Cork University Hospital: Cancer Centre
Country Dispensary for Oncological Diseases, Shumen
Cross Cancer Institute
Dan L. Duncan Cancer Center
Dana-Farber/Harvard Cancer Center
David H. Koch Institute for Integrative Cancer Research at MIT
Delhi State Cancer Institute
Department of Pediatric Hematology and Oncology
Dharmais Hospital - National Cancer Canter
District Dispensary for Oncological Diseases, Plovdiv
Dokuz Eylül University, Institute of Oncology
Duke Cancer Institute
Dundee Cancer Centre
Erasmus MC Daniel den Hoed Cancer Center
European Institute of Oncology
Fakkous Center for Cancer and Allied Diseases
Feist-Weiller Cancer Center
Finsen Centre, Rigshospitalet - Department of Oncology
FN Brno - Department of Pediatric Oncology
Fondazione IRCCS Istituto Nazionale dei Tumori
Fox Chase Cancer Center
Fraser Valley Cancer Centre
Fred and Pamela Buffett Cancer Center
Fred Hutchinson Cancer Research Center
Fudan University Shanghai Cancer Center
Fundacion Instituto Valenciano de Oncologia (IVO)
Galway University Hospital: Cancer Services
General University Hospital in Prague
Georgetown Lombardi Comprehensive Cancer Center
Georgia Regents University - Cancer Centre
Grand River Regional Cancer Centre
Gujarat Cancer & Research Institute / Gujarat Cancer Society
Harold C. Simmons Cancer Center
Helsinki University Central Hospital
Henry Moore Institute of Oncology
Herbert Irving Comprehensive Cancer Center
Herlev Hospital - Department of Oncology
Higashi Sapporo Hospital
Holden Comprehensive Cancer Center
Hollings Cancer Center
Hospital Ceske Budejovice - Comprehensive Cancer Centre
Hospital de Clínicas "Dr. Manuel Quintela"
Huntsman Cancer Institute

Major Cancer Associations Worldwide:

• American Association for Cancer Research
• Virginia Cancer Institute
• American Brain Tumor Association
• American Society of Pediatric Hematology/Oncology
• Association of Cancer Physicians
• American Childhood Cancer Organization
• American Society of Clinical Oncology
• Australasian Lung Cancer Trials Group
• International Cancer Research Partnership (ICRP)
• American Association for Cancer Research (AACR)
• American Society of Clinical Oncology (ASCO)
• International Agency for Research on Cancer (IARC)
• Cancer Society of New Zealand
• Irish Cancer Society
• Australian Cervical Cancer Foundation
• Medical Centre Cologne
• Cancer Research UK
• Australian Prostate Cancer Research
• Peter McCollum Cancer Centre
• The European Cancer Organization (ECCO)
• German Cancer Research Centre

In Asia Pacific

• Medical Excellence JAPAN
• Japan Community Health care Organization Chukyo Hospital
• Aichi Cancer Center Hospital
• Japanese Red Cross Nagoya Daiichi Hospital
• Kyoto University Hospital
• Dokkyo Medical University Hospital
• Japan Hospital Association
• Aizawa Hospital
• Medical Excellence JAPAN
• Japan Community Health care Organization Chukyo Hospital
• Aichi Cancer Center Hospital
• Japanese Red Cross Nagoya Daiichi Hospital
• Kyoto University Hospital
• Dokkyo Medical University Hospital
• Japan Hospital Association
• Aizawa Hospital
• University Hospital Kumamoto University
• International Medical Center of Japan
• The Asia-Pacific Urogynecology Association
• The Asia-Pacific Cancer Society Training
• Asian Cancer Foundation India
• The Max Foundation
• Childhood Cancer International Netherlands
• The Asia Pacific Prostate Society

Market Analysis Report

The cancer diagnostics market is expected to grow at a CAGR of 11.8% during the forecast period 2017-2023. There are several methods of diagnosing cancer today such as biopsy based, endoscopy based, imaging procedure, tumour cancer diagnostics and many more. Population affected with cancer is showing a tremendous growth during last few years, which create the requirement of advanced technology for diagnosis cancer on early stage. According to the American Cancer Society, in 2017, it is estimate that around 161,360 new cases of prostate cancer will be diagnosed and around 26,730 deaths occur owing to prostate cancer in the United States. Thus, many companies are involved in collaboration in order to provide better technology for diagnosis the cancer. In this regards, in January, 2015, Roche and Qualcomm Incorporated entered into a strategic collaboration to improve remote monitoring and management of patients with chronic disease.
The total cost of cancer therapeutics and medicines used in supportive care– measured at the ex-manufacturer price level before the application of rebates or other price concessions – reached $107 billion in 2015, representing an increase in constant dollars of 11.5% over the prior year.

Annual growth in the oncology drug market is expected to be 7.5 – 10.5 % through 2020, reaching $150 billion. Wider utilization of new products—especially immunotherapies—will drive much of the growth, offset by reduced use of some existing treatments with inferior clinical outcomes.

about $51.2 billion in 2017 and is expected to reach $66.4 billion in 2019, registering a compound annual growth rate (CAGR) of 5.4% for the period 2014-2019. It includes current issues and trends affecting the industry, costs and factors influencing demand. The report covers biological products in development, biological products in clinical trials, and currently marketed and late-stage development biologic cancer products.